Fiche publication
Date publication
avril 2025
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Vieujean S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Despite significant advances in the therapeutic management of Crohn's disease (CD), a subset of patients remains refractory to available treatments. Dual-targeted therapy (DTT), combining biologics or biologics with small molecules, has emerged as a promising approach. While evidence supporting DTT continues to grow, reports of patients treated with a combination of three biologic or targeted agents remain exceptionally rare.
Référence
J Crohns Colitis. 2025 04 19;:
